Emtricitabine: A Once-Daily Nucleoside Reverse Transcriptase Inhibitor

US HIV and AIDS cases reported through December 2001 year-end edition. Vol. 13, No. 2. National center for HIV, STD, and TB prevention, Division of HIV/AIDS Prevention. Last updated September 23, 2002. www.cdc.gov/hiv/stats/hasr1302.htm (accessed 2003 Oct 10).

Palella FJ Jr Delaney KM Moorman AC Loveless MO Fuhrer J Satten GA , Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–60.

Raffi F Saag M Cahn P Wolff M Pearce D Molina JM , A randomized, double-blind, multicenter comparison of emtricitabine QD to stavudine BID in treatment-naive HIV-infected patients (abstract). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

Molina JM Ferchal F Journot V Maillard A Noe E Raffi F . Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment-naive HIV-infected adults: 24-month follow-up of the ANRS 091 trial (poster).nce-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment-naive HIV-infected adults: 24-month follow-up of the ANRS 091 trial (poster). Presented at: 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, October 28–31, 2001.

Sanne I van der Horst C Shaw A Hinkle J Quinn JB Moxham C , Two randomized, controlled, equivalence trials of emtricitabine (FTC) to lamivudine (3TC) (poster). Presented at: The XIV International AIDS Conference, Barcelona, July 7–12, 2002.

Shaw A Shen G Wakeford C Quinn JB Rousseau F . Once-daily emtricitabine compared to twice-daily abacavir within a HAART regimen in antiretroviral drug-naive HIV-1 infected patients (ODECTA) (poster).nce-daily emtricitabine compared to twice-daily abacavir within a HAART regimen in antiretroviral drug-naive HIV-1 infected patients (ODECTA) (poster). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, 2003, Paris, July 13–16, 2003.

Wakeford C Shen G Hulett L Quinn JB Rousseau F . Long-term efficacy and safety of emtricitabine in HIV+ adults switching from lamivudine containing HAART regimen (poster). Presented at: 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003.

McKinney R Rathore M Jankelovich S Mofenson L Wang L Reynolds L , PACTG 1021: An ongoing phase I/II study of once-daily emtricitabine, didanosine, and efavirenz in therapy-naive or minimally treated pediatric patients (poster). Presented at: 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003.

Saez-Llorens X Violari A Ndiweni D Avila-Figueroa C Wiznia A Blum MR , Once-daily emtricitabine in HIV-infected pediatric patients with other antiretroviral agents (poster). Presented at: 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003.

Gish R Leung N Wang C Corey L Sacks S Fried M . Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients given once daily emtricitabine (Coviracil®, FTC) for 2 years (poster). Presented at: 53rd Annual Meeting of the American Association for the Study of Liver Diseases, November 1–5, 2002, Boston, MA. Hepatology 2002; 36 (4 part 2): 167A–840A.

Gish RG Leung NW Wright TL Trinh H Lang W Kessler HA , Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002; 46: 1734–40.

Raffi F Snow A Borroto-Esoda K Shaw A Anderson J Sorbel J , Anti-HBV activity of emtricitabine (FTC) in patients co-infected with HIV and hepatitis B virus (abstract). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

Rousseau F Fang L Wang LH Sykes A Rigney A Drobnes C , Emtricitabine (FTC): HBV DNA viral load assessments over 36 weeks in patients with chronic HBV infection (poster). Presented at: 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001.

Emtriva (emtricitabine) package insert: CDER FDA Drug Approvals. Last updated 2003 July 1. www.fda.gov/cder/foi/nda/2003/21-500_Emtriva_Prntlbl.pdf (accessed 2003 Aug 25).

Darque A Valette G Rousseau F Wang LH Sommadossi JP Zhou XJ . Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus—infected patients. Antimicrob Agents Chemother 1999; 43: 2245–50.

Delehanty J Wakeford C Hulett L Quinn B McCreedy B Almond M , A Phase I/II randomized, controlled study of FTC versus 3TC in HIV-infected patients (abstract). Presented at: 6th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1–4, 1999.

Feng JY Shi J Schinazi RF Anderson KS . Mechanistic studies show that (−)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J 1999; 13: 1511–7.

Feng JY Anderson KS . Mechanistic studies comparing the incorporation of (+) and (−) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry 1999; 38: 55–63.

Moore KH Barrett JE Shaw S Pakes GE Churchus R Kapoor A , The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 1999; 13: 2239–50.

Wang L Begly J Feng JY Quinn JB Rousseau F . Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing (poster). Presented at: The XIV International AIDS Conference, Barcelona, July 7–12, 2002.

Schinazi RF McMillan A Cannon D Mathis R Lloyd RM Peck A , Selective inhibition of human immunodeficiency viruses by race-mates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathi-olan-5-yl]cytosine. Antimicrob Agents Chemother 1992; 36: 2423–31.

Mathez D Schinazi RF Liotta DC Leibowitch J . Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob Agents Chemother 1993; 37: 2206–11.

Microbiology review, emtricitabine FDA approval package. Last updated 2003. Center for Drug Evaluation and Research. www.fda.gov/cder/foi/nda/2003/021500_emtriva_toc.htm (accessed 2003 Sept 26).

Hazen R Lanier ER . Relative anti—HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr 2003; 32: 255–8.

Petrella M Wainberg MA . Might the M184V substitution in HIV-1 RT confer clinical benefit? AIDS Reviews 2002; 4: 224–32.

Gu Z Gao Q Fang H Salomon H Parniak MA Goldberg E , Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′, 3′-dideoxycytidine and 2′, 3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994; 38: 275–81.

Gu Z Fletcher RS Arts EJ Wainberg MA Parniak MA . The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′, 3′-dideoxycytidine, 2′, 3′-dideoxy-3′-thiacytidine, and 2′, 3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J Biol Chem 1994; 269: 28118–22.

Hertogs K Bloor S De Vroey V van Den EC Dehertogh P van Cauwenberge A , A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother 2000; 44: 568–73.

Schinazi RF Lloyd RM Jr Nguyen MH Cannon DL McMillan A Ilk-Soy N , Characterization of human immunodeficiency viruses resistant to oxathiolane—cytosine nucleosides. Antimicrob Agents Chemother 1993; 37: 875–81.

Cahn P Raffi F Wolff M Pearce D Molina JM Borroto-Esoda KE , Virologic efficacy and patterns of resistance mutations in ART-naïve patients receiving combination therapy with once-daily emtricitabine compared to twice-daily stavudine in a randomized, double-blind, multicenter clinical trial (poster). Presented at: 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003.

Sanne I Quinn JB Harris J Shaw A Hinkle J Borroto-Esoda K , Genotypic analysis of HIV-1 infected ART-naive patients receiving emtricitabine (FTC) or lamivudine (3TC) in a double blind equivalence trial (poster). Presented at: XIV International AIDS Conference, Barcelona, July 7–12, 2002.

Borroto-Esoda K Waters J Quinn JB Shaw A Hinkle J Rousseau F . Characterization of baseline and treatment-emergent resistance mutations following 1 year of therapy on an entirely once a day regimen including emtricitabine (poster). Presented at: XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, June 10–14, 2003. Antiviral Ther 2003; 8: S10.

Rousseau FS Kahn JO Thompson M Mildvan D Shepp D Sommadossi JP , Prototype trial design for rapid dose selection of antiretroviral drugs: An example using emtricitabine (Coviracil). J Antimicrob Chemother 2001; 48: 507–13.

Study FTC-101 in clinical pharmacology and biopharmaceutics review, Emtricitabine FDA approval package. Center for Drug Evaluation and Research. Last updated 2003. www.fda.gov/cder/foi/nda/2003/021500_emtriva_toc.htm (accessed 2003 Sept 26).

Study FTC-110 in clinical pharmacology and biopharmaceutics review, Emtricitabine FDA approval package. Center for Drug Evaluation and Research. Last updated 2003. www.fda.gov/cder/foi/nda/2003/021500_emtriva_toc.htm (accessed 2003 Sept 26).

Study FTC-111 in clinical pharmacology and biopharmaceutics review, Emtricitabine FDA approval package. Center for Drug Evaluation and Research. Last updated 2003. www.fda.gov/cder/foi/nda/2003/021500_emtriva_toc.htm (accessed 2003 Sept 26).

Study PDM-037 in clinical pharmacology and biopharmaceutics review, Emtricitabine FDA approval package. Center for Drug Evaluation and Research. Last updated 2003. www.fda.gov/cder/foi/nda/2003/021500_emtriva_toc.htm (accessed 2003 Sept 26).

Borroto-Esoda K Benson C Quinn J Hinkle J Harris J Moxham C , Predictors of virologic failure in HIV-1 infected adults on a stable lamivudine HAART regimen (poster). Presented at: XI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Seville, Spain, July 2–5, 2002.

Study FTC-106 in clinical pharmacology and biopharmaceutics review, Emtricitabine FDA approval package. Center for Drug Evaluation and Research. Last updated 2003. www.fda.gov/cder/foi/nda/2003/021500_emtriva_toc.htm (accessed 2003 Sept 26).

Study FTC-107 in clinical pharmacology and biopharmaceutics review, Emtricitabine FDA approval package. Center for Drug Evaluation and Research. Last updated 2003. www.fda.gov/cder/foi/nda/2003/021500_emtriva_toc.htm (accessed 2003 Sept 26).

Wang LH Blum MR Hui J Hulett L Chittick GE Rousseau F . Lack of significant pharmacokinetic interactions between emtricitabine and other nucleoside antivirals in healthy volunteers (abstract). Presented at: 41st Interscience Conference on Antimicrobial Agents & Chemotherapy, Chicago, December 16–20, 2001.

Study FTC-108 in clinical pharmacology and biopharmaceutics review, Emtricitabine FDA approval package. Center for Drug Evaluation and Research. Last updated 2003. www.fda.gov/cder/foi/nda/2003/021500_emtriva_toc.htm (accessed 2003 Sept 26).

Study FTC-103 in clinical pharmacology and biopharmaceutics review, Emtricitabine FDA approval package. Center for Drug Evaluation and Research. Last updated 2003. www.fda.gov/cder/foi/nda/2003/021500_emtriva_toc.htm (accessed 2003 Sept 26).

Zong J . A steady-state evaluation of the potential pharmacokinetic interaction between emtricitabine and zidovudine in healthy volunteers (poster). Presented at: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14–17, 2003.

Chiu YL Foit C Gathe J Podzamczer D Johnson M Clotet B , Multiple-dose pharmacokinetics (PK) and initial antiviral effect of once daily (QD) lopinavir/ritonavir (LPV/r) in combination with tenofovir (TDF) and emtricitabine (FTC) in HIV-infected antiretroviral (ARV)-naive subjects (abstract). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

Study FTC-114 in clinical pharmacology and biopharmaceutics review, Emtricitabine FDA approval package. Center for Drug Evaluation and Research. Last updated 2003. www.fda.gov/cder/foi/nda/2003/021500_emtriva_toc.htm (accessed 2003 Sept 26).

Molina JM Ferchal F Rancinan C Raffi F Rozenbaum W Sereni D , Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus—infected patients. J Infect Dis 2000; 182: 599–602.

Saag M Cahn P Raffi F Wolff M Pearce D Molina J , A randomized, double-blind, multicenter comparison of emtricitabine QD to stavudine BID (abstract). Presented at: 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy, San Diego, September 27–30, 2002.

Study FTC-302 in the medical review, Emtricitabine FDA approval package. Center for Drug Evaluation and Research. Last updated 2003. www.fda.gov/cder/foi/nda/2003/021500_emtriva_toc.htm (accessed 2003 Sept 26).

Molina JM Ferchal F Rancinan C Yéni P Rozenbaum W Journot V , Once-daily combination of emtricitabine, didanosine, and efavirenz vs continued PI-based HAART in HIV-infected adults with undetectable plasma HIV-RNA: 48-week results of a prospective randomized multicenter trial (ALIZE-ANRS 99) (poster). Presented at: 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10–14, 2003.

Molina JM Ferchal F Journot V Yéni P Rozenbaum W Rancinan C , Emtricitabine, didanosine and efavirenz once-daily (OD) versus continued PI-based HAART (c) in HIV-infected adults with undetectable plasma HIV-RNA: 48-week results of a prospective randomized multicenter trial (ALIZE-ANRS 99) (abstract). Presented at: 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

Landman R Schiemann R Thiam S Vray M Canestri A Mboup S , Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1—infected adults in Senegal. AIDS 2003; 17: 1017–22.

Maggiolo F Migliorino M Maserati R Pan A Rizzi M Provettoni G , Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antiviral Ther 2001; 6: 249–53.

Moya J Casado JL Diz S Moreno A Antela A Dronda F , Efficacy and safety of a once daily regimen with NNRTIs after a successful protease inhibitor—containing regimen (abstract). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

Jordan W Jefferson R Yemofio F Tolbert L Conlan V Carroll H , Nevirapine (NVP) + efavirenz (EFV) + didanosine (ddI): A very simple, safe, and effective once-daily regimen (abstract). Presented at: XIII International AIDS Conference, Durban, South Africa, July 9–14, 2000.

Mole L Schmidgall D Holodniy M . A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection. J Acquir Immune Defic Syndr 2001; 27: 260–5.

Farthing C Khanlou H Yeh V . Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients (abstract). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

Guidelines for the use of antiretroviral agents in HIV-1—infected adults and adolescents: Panel on Clinical Practices for Treatment of HIV Infection. Last updated July 14, 2003. http://aidsinfo.nih.gov/guidelines (accessed 2003 Oct 5).

Parienti JJ Verdon R Bazin C . Once-daily regimen may increase drug holidays. J Infect Dis 2001; 183: 1539–40.

Molina JM Noé E Raffi F Rozenbaum W Morlat P Rancinan C , Once-daily combination therapy with emtricitabine (FTC), didanosine (ddI) and efavirenz (EFV) in treatment naive HIV-infected adults: 3-year follow-up of the Montana (ANRS 091) trial (poster). Presented at: 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

Powderly W Mondou R Shaw A Wakeford C Adda N Quinn JB , Overview of the incidence of symptomatic hyperlactatemia with emtricitabine (FTC) (abstract). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13–16, 2003.

Sidley P . South Africa to tighten control on drug trials after five deaths. BMJ 2000; 320: 1028.

Package insert. Viramune (nevirapine). Ridgefield, CT: Boehringer Ingelheim, 2003.

Bartlett J . Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor (abstract). Presented at: 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001.

Wiznia A Wang L Rathore M Chittick G Bakshi S Flynn P . An evaluation of the pharmacokinetics and safety of single oral doses of emtricitabine (FTC) in HIV-infected or exposed children (poster). Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000.